Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Alphamab Approved to Start US Trial of PD-L1/CTLA-4 Bispecific

publication date: Mar 9, 2021

Jiangsu Alphamab Oncology was approved to start a US Phase II trial of its PD-L1/CTLA-4 bispecific antibody in patients with thymic carcinoma, a rare disease. Alphamab said inoperable or metastatic thymic carcinoma, although rare, is highly aggressive with no approved treatments. In an Australian Phase I trial, KN046 showed a 75% disease response rate and 100% disease control rate in patients with the disease. Alphamab has already dosed the first thymic carcinoma patient in a pivotal China Phase II trial. More details....

Stock Symbol: (HK: 9966)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.